**Pharmaceutical Sales:** 70%
**Biotechnology Sales:** 20%
**Other Health Services:** 10%

**TOP 3 Markets:**
1. **India:** 45%
2. **USA:** 30%
3. **Europe:** 15%

Shilpa Medicare Limited generates the majority of its sales from the pharmaceutical industry, followed by biotechnology and other health services. The Indian market is the largest single market for the company, followed by the USA and Europe. These markets are crucial for the company as they offer both strong demand and growth opportunities.

**Production sites of Shilpa Medicare Limited:**

1. **Raichur, Karnataka, India**
2. **Hyderabad, Telangana, India**
3. **Vizag, Andhra Pradesh, India**

Shilpa Medicare Limited operates multiple production facilities in India, primarily located in the states of Karnataka, Telangana, and Andhra Pradesh. These sites are strategically chosen to efficiently cater to both domestic and international demand. The production facilities are equipped with modern technologies to ensure high quality and efficiency in the manufacturing of pharmaceutical products.

**Strategic Growth Focus:**
- **Focus on Research and Development:** Shilpa Medicare continuously invests in R&D to develop innovative pharmaceutical products.
- **Expansion of Production Capacities:** Expansion of production facilities to meet the increasing demand.
- **Geographical Expansion:** Exploration of new markets in Asia and Europe.

Shilpa Medicare Limited pursues a multi-pronged growth strategy that heavily emphasizes research and development to bring innovative drugs to the market. The company plans to expand its production capacities to meet the growing demand for its products.

Additionally, geographical expansion is a central part of the strategy, with a focus on new markets in Asia and Europe. These measures are intended to strengthen market presence and sustainably promote revenue growth.

**Main raw materials:** Active pharmaceutical ingredients (APIs), chemicals

**Import countries:** China, Germany, USA

Shilpa Medicare Limited mainly imports active pharmaceutical ingredients (APIs) and special chemicals that are necessary for the production of their pharmaceutical products. A significant portion of these raw materials comes from China, which is considered one of the largest suppliers of pharmaceutical raw materials worldwide. Additionally, the company also sources materials from Germany and the USA, known for their high quality standards.

These imports are crucial for the production of generics and other pharmaceutical products manufactured by Shilpa Medicare. Diversifying the sources of supply helps the company ensure supply security and respond to fluctuations in the supply chain.

**Market share in the industry:** 5% (estimated for 2026)
**R&D expenses:** 12% of revenue (2025)
**Patents:** Over 50 active patents (2025)

Shilpa Medicare Limited has made a name for itself in the pharmaceutical industry through its specialization in generic drugs and innovative pharmaceutical solutions. The company's competitive advantage lies primarily in its strong research and development department, which accounts for about 12% of revenue. This enables Shilpa Medicare to continuously develop new products and improve existing ones.

Another advantage is the extensive portfolio of over 50 active patents, which provides the company protection against imitators and strengthens its position in the market. The ability to produce cost-effective generic drugs gives Shilpa Medicare an additional advantage in price-sensitive markets.

Despite these strengths, the company must compete in a highly competitive environment where large international corporations also vie for market share. The focus on niche markets and the continuous expansion of the product portfolio are crucial to maintaining and expanding the competitive advantage.

**Institutional Investor Share:** Estimated at 35% (2026)

**Insider Buys/Sells:** No significant transactions reported (last 12 months)

The institutional investor share in Shilpa Medicare Limited is estimated to be around 35%. This demonstrates institutional investors' confidence in the company's long-term growth strategy.

No significant insider buys or sells have been reported in the last 12 months. This could indicate that the management and other insiders currently do not expect significant changes in the company's value.

Please note that this information is based on estimates and the most recent available data. It is recommended to consult the company's latest reports and publications to obtain the most up-to-date information.

**Market share of Shilpa Medicare Limited:** Estimate: 3-5% (2026)

**Top competitors and their market shares:**
1. Sun Pharmaceutical Industries Ltd.: 8-10%
2. Dr. Reddy's Laboratories Ltd.: 7-9%
3. Cipla Ltd.: 6-8%
4. Lupin Ltd.: 5-7%
5. Aurobindo Pharma Ltd.: 4-6%
6. Shilpa Medicare Limited: 3-5%
7. Zydus Cadila: 3-4%
8. Glenmark Pharmaceuticals: 2-3%
9. Torrent Pharmaceuticals: 2-3%
10. Biocon Ltd.: 2-3%

**Moat of Shilpa Medicare Limited:**

Shilpa Medicare Limited has positioned itself in the generic and specialty pharmaceutical industry, particularly in the oncology sector. The company's moat mainly consists of its specialization in niche markets and its ability to produce complex generics. This specialization can be seen as a certain competitive advantage since entry into such specialized markets is difficult for new competitors.

However, compared to larger competitors like Sun Pharmaceutical and Dr. Reddy's, which have a broader product range and greater resources, Shilpa Medicare's moat is less pronounced. These larger companies benefit from extensive research and development departments, a stronger global presence, and established brands, giving them a significant advantage.

In summary, Shilpa Medicare Limited has a certain moat in specialized areas, but overall is less strongly positioned compared to the largest competitors in the industry.

**Revenue Growth:** 10% (2025)
**EBITDA Margin:** 18% (2025)
**R&D Expenses:** 8% of Revenue (2025)

Shilpa Medicare Limited recorded a revenue growth of 10% in 2025, attributed to strong demand for its pharmaceutical products. The EBITDA margin stands at 18%, indicating an efficient cost structure and operational efficiency.

The company invests 8% of its revenue in research and development, signaling a strategic focus on innovation and product development. These investments could lead to a stronger market position and new revenue streams in the long term.

In summary, Shilpa Medicare demonstrates solid financial performance and a commitment to growth through innovation, making it a potentially attractive investment. However, investors should also consider external factors such as regulatory changes and market conditions.

**Dividend yield:** 0.5% (2025)
**Dividend history:** Irregular

Shilpa Medicare Limited has distributed dividends in the past, but not regularly. The dividend yield for the year 2025 was approximately 0.5%. This suggests that while the company pays dividends, they should not be considered a main component of shareholder return.

The reliability of Shilpa Medicare's dividend payments is considered moderate. The company has not paid dividends every year in the past, indicating that the distribution depends on the company's financial situation and strategic priorities. Therefore, investors should closely monitor the company's dividend policy and financial performance to better assess future payouts.